Peptic Ulcer Drugs Market By Drug Type (Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists (H2RAs), Antacids, Cytoprotective Agents), By Route of Administration (Oral, Intravenous, Topical), By End-User (Hospitals & Clinics, Gastroenterology Centers, Pharmacies), By Distribution Channel (Direct Sales, Distributors, Online Retailers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Peptic Ulcer Drugs Market was valued at USD 3.7 billion in 2024-e and will surpass USD 5.9 billion by 2030; growing at a CAGR of 8.5% during 2025 - 2030.

The peptic ulcer drugs market is experiencing steady growth driven by the increasing incidence of peptic ulcers worldwide and the rising awareness of gastrointestinal disorders. Peptic ulcers, which include both gastric and duodenal ulcers, are commonly caused by factors such as Helicobacter pylori infection, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), and excessive alcohol consumption. The market is characterized by a variety of treatment options, including proton pump inhibitors (PPIs), H2-receptor antagonists (H2RAs), antacids, and cytoprotective agents. These drugs aim to reduce stomach acid, protect the stomach lining, and promote healing.

Advancements in drug formulations and the development of combination therapies have expanded treatment options for patients, offering more effective and tailored approaches. In particular, PPIs dominate the market due to their potent ability to inhibit stomach acid production, improving healing rates and providing relief from ulcer symptoms. As the prevalence of peptic ulcers remains high in developing countries and with increasing healthcare access, the demand for peptic ulcer drugs is expected to continue rising in the coming years.

Proton Pump Inhibitors (PPIs) Segment is Largest Owing to Efficacy in Treating Peptic Ulcers

The proton pump inhibitors (PPIs) segment is the largest in the peptic ulcer drugs market due to their high efficacy in treating peptic ulcers. PPIs work by inhibiting the proton pumps in the stomach lining that are responsible for producing stomach acid. This results in a significant reduction in acid production, allowing the ulcer to heal and reducing associated symptoms such as pain and discomfort. PPIs are considered the first-line therapy for treating peptic ulcers, particularly in cases caused by H. pylori infection or the long-term use of NSAIDs.

The widespread adoption of PPIs in both hospital and outpatient settings has contributed to their dominance in the market. Additionally, PPIs are available in both prescription and over-the-counter formulations, making them easily accessible to a wide range of patients. As a result, PPIs continue to hold a significant share of the peptic ulcer drugs market, with their use being supported by extensive clinical evidence and a well-established safety profile.

Oral Route of Administration is Largest Owing to Patient Convenience and Compliance

The oral route of administration is the largest in the peptic ulcer drugs market due to its ease of use, patient convenience, and improved compliance. Oral medications, such as PPIs and H2RAs, are preferred by both patients and healthcare providers because they allow for self-administration, eliminating the need for hospital visits or intravenous treatments. This is particularly beneficial for patients who require long-term treatment for peptic ulcers, as oral medications can be taken at home without the need for specialized healthcare interventions.

Oral medications also offer patients flexibility in terms of dosing and frequency, which further enhances patient adherence to treatment regimens. Given the convenience and affordability of oral formulations, the oral route of administration remains the preferred option in treating peptic ulcers, contributing to the continued growth of the segment.

Hospitals & Clinics Segment is Largest End-User Owing to Need for Medical Supervision

The hospitals and clinics segment is the largest end-user in the peptic ulcer drugs market due to the high level of medical supervision required for the treatment of peptic ulcers. Hospitals and clinics provide the necessary infrastructure for diagnosing and managing complicated cases of peptic ulcers, including those requiring intravenous treatments or monitoring for complications such as gastrointestinal bleeding.

Patients with more severe forms of peptic ulcers or those at risk of complications often seek care in hospital or clinic settings, where healthcare providers can offer tailored treatment plans and more intensive care when needed. This reliance on hospitals and clinics for treatment and management ensures that they remain the dominant end-users in the market for peptic ulcer drugs.

North America is Largest Region Owing to High Prevalence and Access to Healthcare

North America is the largest region in the peptic ulcer drugs market, owing to the high prevalence of gastrointestinal disorders and advanced healthcare systems in the region. The United States and Canada have a large patient population suffering from peptic ulcers, driven by factors such as diet, stress, and the widespread use of NSAIDs. The availability of advanced treatments, including PPIs and H2RAs, has led to a high treatment rate in the region, further bolstering the market's growth.

In addition, North America has a well-established healthcare infrastructure, ensuring that patients have easy access to both prescription and over-the-counter medications. The strong presence of pharmaceutical companies in the region, combined with ongoing research into new drug formulations, supports continued growth in the peptic ulcer drugs market.

Competitive Landscape

The peptic ulcer drugs market is highly competitive, with several key pharmaceutical companies dominating the landscape. Leading companies focus on developing innovative drug formulations and expanding their portfolios to include both branded and generic products. The dominance of proton pump inhibitors (PPIs) in the market has prompted pharmaceutical companies to enhance their product offerings by introducing new versions of PPIs with improved safety profiles and extended-release formulations.

In addition to large pharmaceutical companies, the market also includes several generic drug manufacturers that contribute to making treatment more affordable and accessible. The competition in the market is driven by factors such as pricing, product differentiation, and the development of new formulations that improve treatment outcomes and patient adherence. With ongoing research into combination therapies and novel drug classes, the competitive landscape of the peptic ulcer drugs market is expected to continue evolving in the coming years.

List of Leading Companies:

• Pfizer
• AstraZeneca
• Johnson & Johnson
• GlaxoSmithKline
• Novartis
• Takeda Pharmaceutical Company
• Sanofi
• Merck & Co.
• Mylan N.V.
• Eli Lilly and Company
• Boehringer Ingelheim
• Abbott Laboratories
• Gilead Sciences
• Bausch Health Companies
• Cipla

Recent Developments:

• In December 2024, Pfizer launched a new proton pump inhibitor for peptic ulcer treatment in multiple regions.
• In November 2024, AstraZeneca received approval for a new oral ulcer drug combination for faster healing.
• In October 2024, GlaxoSmithKline introduced an over-the-counter version of its H2-receptor antagonist for ulcer relief.
• In September 2024, Takeda Pharmaceutical Company expanded its ulcer drug portfolio with a new cytoprotective agent.
• In August 2024, Mylan N.V. launched a generic version of a popular antacid for peptic ulcer relief.

Report Scope: